Volume 35, Issue 6 , Pages 992-997, June 2009
Dissatisfaction after multifocal intraocular lens implantation
Purpose
To analyze the reasons for patient dissatisfaction after phacoemulsification with multifocal intraocular lens (IOL) implantation and the outcomes after intervention.
Setting
Emory Eye Center, Atlanta, Georgia, USA.
Methods
This retrospective review comprised eyes of patients dissatisfied with visual outcomes after multifocal IOL implantation. Outcomes analyzed included type of visual complaint, treatment modality for each complaint, and degree of clinical improvement after intervention.
Results
Thirty-two patients (43 eyes) reported unwanted visual symptoms after multifocal IOL implantation, including in 28 eyes (65%) with an AcrySof ReSTOR IOL and 15 (35%) with a ReZoom IOL. Thirty patients (41 eyes) reported blurred vision, 15 (18 eyes) reported photic phenomena, and 13 (16 eyes) reported both. Causes of blurred vision included ametropia (12 eyes, 29%), dry eye syndrome (6 eyes, 15%), posterior capsule opacification (PCO) (22 eyes, 54%), and unexplained etiology (1 eye, 2%). Causes of photic phenomena included IOL decentration (2 eyes, 12%), retained lens fragment (1 eye, 6%), PCO (12 eyes, 66%), dry-eye syndrome (1 eye, 2%), and unexplained etiology (2 eyes, 11%). Photic phenomena attributed to PCO also caused blurred vision. Thirty-five eyes (81%) had improvement with conservative treatment. Five eyes (12%) did not have improvement despite treatment combinations. Three eyes (7%) required IOL exchange.
Conclusions
Complaints of blurred vision and photic phenomena after multifocal IOL implantation were effectively managed with appropriate treatment. Few eyes (7%) required IOL exchange. Neodymium:YAG capsulotomy should be delayed until it has been determined that IOL exchange will not be necessary.
To access this article, please choose from the options below
Dr. Randleman is a consultant to Alcon, Allergan, and Ista. Dr. Stulting is a consultant to Alcon and Abbott Medical Optics. Dr. Woodward has no financial or proprietary interest in any material or method mentioned.
Supported in part by Research to Prevent Blindness, Inc., New York, New York, and the National Institutes of Health Core Grant P30 EYO6360, Bethesda, Maryland, USA.
PII: S0886-3350(09)00256-9
doi:10.1016/j.jcrs.2009.01.031
© 2009 ASCRS and ESCRS. Published by Elsevier Inc. All rights reserved.
Volume 35, Issue 6 , Pages 992-997, June 2009
